Financial health
- Operating income covered interest expense -557.7× in the latest year, up from -889.1× 5 years ago.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$6M | — | — | — | — | — |
| 2024 | — | -$4M | — | — | — | — | — |
| 2023 | — | -$5M | — | — | — | — | $4M |
| 2022 | — | -$6M | — | — | — | — | $5M |
| 2021 | — | -$7M | — | — | — | — | $5M |
| 2020 | — | -$3M | — | — | — | — | $5M |
| 2019 | — | -$2M | — | — | — | — | $3M |
| 2018 | — | -$2M | — | — | — | — | $4M |
| 2017 | — | -$2M | — | — | — | — | $1M |
| 2016 | — | -$2M | — | — | — | — | $199929 |
| 2015 | $200000 | -$3M | 0.0% | -1323.2% | — | — | $25281 |
| 2014 | — | -$3M | — | — | — | — | $44411 |
| 2014 | — | -$14M | — | — | — | — | $115440 |
| 2013 | $0 | -$1M | — | — | — | — | $475019 |
| 2013 | $0 | -$13M | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | — | — | — |
| Mar '25 | — | -$709555 | — | — | — | — | — |
| Dec '13 | $0 | — | — | — | — | — | $475019 |
| Sep '13 | $0 | — | — | — | — | — | — |
| Jun '13 | $0 | — | — | — | — | — | — |
| Mar '13 | $0 | — | — | — | — | — | — |
| Dec '12 | $0 | — | — | — | — | — | $2M |
| Sep '12 | $0 | — | — | — | — | — | — |
| Jun '12 | $0 | — | — | — | — | — | — |
| Mar '12 | $0 | — | — | — | — | — | — |
| Dec '11 | $0 | — | — | — | — | — | — |
| Sep '11 | $0 | — | — | — | — | — | — |
| Jun '11 | $0 | — | — | — | — | — | — |
| Mar '11 | $0 | — | — | — | — | — | — |
| Dec '10 | $0 | — | — | — | — | — | — |
| Sep '10 | $0 | — | — | — | — | — | — |
| Jun '10 | $0 | — | — | — | — | — | — |
See the revenue and net-income charts above for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s multi-year trend.
As of FY2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported — of total debt against — of cash; operating income covered interest expense -557.7×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.